Cologne, Germany, 01.07.2021 – The book series, ‘Colloquium Senologie’ targets all doctors that devote themselves to the care of breast cancer patients. Together with their team of authors, the editors describe the practice-relevant developments in breast cancer treatment of the previous twelve months. In addition to the state of the art and important findings from […]
CANKADO contributes to ‘Colloquium Senology 2021/2022’ Read More »
Cologne, Germany, 26.05.2021 – CANKADO’s digital health application (Digitale Gesundheitsanwendung, DiGA) called PRO-React Onco was approved by the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM). PRO-React Onco is now listed in the DiGA Directory and available for breast cancer patients upon prescription. Legal background of DiGA The Digital Healthcare
Germany’s first DiGA for Breast Cancer Patients Read More »
Cologne, Germany, 07.01.2021 – CANKADO (https://partners.cankado.com/), the leading digital health application developers in Germany, assists the recently started clinical trial, ADAPTlate, organized by West German Study Group (WSG) to collect the Patient Reported Outcomes (PROs) by the CANKADO ePRO tool (https://partners.cankado.com/epro/). The clinical trial already enrolled the first patients who are using the CANKADO e-Health
CANKADO’s Digital Health Solution Assists a New Clinical Trial, ADAPTlate Read More »
Cologne, Germany, 17.12.2020 – CANKADO’s (https://partners.cankado.com/) Companion-APP solution provides an environment that helps to build a drug-tailored digital connected care solution for physicians and their patients. Pharmaceutical companies can easily develop their own multi-dimensional drug-optimized digital support for every drug and treatment. It improves patient safety, increases patient compliance, and prolongs drug adherence for a
Cologne, Germany, 11.12.2020 – The EnReP (Endocrine Response Predictor) assessment tool will be presented today at the San Antonio Breast Cancer Symposium SABCS 2020. EnReP is a tool developed in Germany that can be used to predict the probability of response to endocrine therapy in early-stage breast cancer patients. Endocrine therapy is the standard therapy
